Publications by authors named "S Tcherny-Lessenot"

Claim this Profile
S
Suitability of Preference Methods Across the Medical Product Lifecycle: A Multicriteria Decision Analysis.
Jorien Veldwijk, Esther de Bekker-Grob, Juhaeri Juhaeri, Eline van Overbeeke, Stephanie Tcherny-Lessenot

Value Health· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment preferences for preventive interventions for rheumatoid arthritis: protocol of a mixed methods case study for the Innovative Medicines Initiative PREFER project.
Marie Falahee, Gwenda Simons, Rachael L DiSantostefano, Larissa Valor Méndez, Christine Radawski, Stephanie Tcherny-Lessenot

BMJ Open· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of risk minimisation measures for valproate: A cross-sectional survey among physicians in Europe.
Massoud Toussi, Bardoulat Isabelle, Stephanie Tcherny-Lessenot, Hanka de Voogd, Vasilis Dimos

Pharmacoepidemiol Drug Saf· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structured benefit-risk evaluation for medicinal products: review of quantitative benefit-risk assessment findings in the literature.
Marie-Laure Kürzinger, Ludivine Douarin, Ievgeniia Uzun, Chantal El-Haddad, William Hurst, Stéphanie Tcherny-Lessenot

Ther Adv Drug Saf· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre/post effectiveness evaluation of updated additional risk minimisation measures for an orphan disease: Myozyme (alglucosidase alfa) Safety Information Packet.
Esther Artime, Irene Shui, Ignacio Mendez, Stephanie Tcherny-Lessenot, Pierre D'Arbigny

Pharmacoepidemiol Drug Saf· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis